albuterol (Armstrong Albuterol HFA) vs Salbutamol HFA-152a

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol (Armstrong Albuterol HFA)

Marketed by Amphastar Pharmaceuticals, Inc.

Approved in Asthmasmall molecule
Partial signal

NCT00634829 · Phase 3 · terminated

This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Next expected readout: April 2028 · NCT07426458 (registry estimate)

No aligned efficacy figure on record for this race.

Salbutamol HFA-152a

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Weak signal

NCT06261957 · Phase 3 · completed

The trial randomized 471 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs) During Run-in Period" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: April 2027 · NCT06433921 (registry estimate)

Reported efficacy

Number of participants with Adverse Events (AEs) (Up to 3 months): Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). (not_applicable)

Result source: NCT06261957

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol (Armstrong Albuterol HFA)Salbutamol HFA-152a
Severe exacerbations, annualised rate—Not posted · NCT00667407—Not reported
Trough FEV1, change—Not posted · NCT00667407—Not reported
ACQ-5, change—Not posted · NCT00667407—Not reported
OCS dose reduction—Not posted · NCT00667407—Not reported

Severe exacerbations, annualised rate

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Salbutamol HFA-152a
—Not reported

Trough FEV1, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Salbutamol HFA-152a
—Not reported

ACQ-5, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Salbutamol HFA-152a
—Not reported

OCS dose reduction

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Salbutamol HFA-152a
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Salbutamol HFA-152a
Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). NCT06261957 · Phase 3 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol (Armstrong Albuterol HFA): 0 of 4 rows · Salbutamol HFA-152a: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSalbutamol HFA-152a
Dropout rate
—800 uga
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—800 uga
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
—200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Serious AEs
0%800 uga
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
3.3%200 ug
NCT06433908 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
800 uga
catheter site related reaction 30%
headache 16.7%
cough 10%
NCT06433908 · Phase 1 · registry result, not featured evidence
show 1 more result
200 ug
catheter site haematoma 16.7%
headache 10%
abdominal pain 6.7%
NCT06433908 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · Salbutamol HFA-152a's landscape